The Virtual Diabetes Control and Complications Trial (DCCT): Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications
Authors' conclusion
Fourteen-day CGM metrics predicted microvascular diabetes complications similarly to glycated hemoglobin.
Study context
- Population
- DCCT participants with T1D
- Comparison
- Time-in-range (TIR) from virtual continuous glucose monitoring (CGM) vs HbA1c for prediction of microvascular complications
Methodological detailsmultistep machine-learning procedure, virtual CGM traces
- Multistep machine-learning procedure
- Virtual CGM traces
Primary result
As reported in the abstract
Association of TIR (70-180 mg/dL) from virtual CGM with microvascular complications · 14 days prior to each HbA1c measurement
- TIR associated with risk of development or progression of retinopathy, nephropathy and neuropathy
- all P-values <0.0001
Further findings
| Outcome | Intensive | Conventional |
|---|---|---|
| TIR by DCCT group · 14 days prior to each HbA1c measurementTIR generally | >60% | <40% |
TIR by DCCT group · 14 days prior to each HbA1c measurement
- Virtual CGM TIR reproduced observed glycemic control differences between groups
Original publication
The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications. Diabetes Technol Ther. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →